Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference
Lipocine (NASDAQ: LPCN), a biopharmaceutical company focused on innovative oral drug delivery, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The company's presentation will be available starting September 5, 2025, at 7:00 a.m. EDT.
The conference will be held in both in-person and virtual formats. Investors interested in one-on-one meetings with Lipocine management should coordinate through their H.C. Wainwright representatives.
Lipocine (NASDAQ: LPCN), societ脿 biofarmaceutica specializzata in innovative formulazioni orali, parteciper脿 alla H.C. Wainwright 27th Annual Global Investment Conference dall'8 al 10 settembre 2025. La presentazione della societ脿 sar脿 disponibile a partire dal 5 settembre 2025 alle 7:00 EDT.
La conferenza si svolger脿 sia in presenza sia in modalit脿 virtuale. Gli investitori interessati a incontri individuali con il management di Lipocine devono organizzare gli appuntamenti tramite i propri rappresentanti H.C. Wainwright.
Lipocine (NASDAQ: LPCN), una compa帽铆a biofarmac茅utica centrada en novedosas formulaciones orales, participar谩 en la H.C. Wainwright 27th Annual Global Investment Conference del 8 al 10 de septiembre de 2025. La presentaci贸n de la empresa estar谩 disponible desde el 5 de septiembre de 2025 a las 7:00 a.m. EDT.
La conferencia se celebrar谩 tanto de forma presencial como virtual. Los inversores interesados en reuniones individuales con la direcci贸n de Lipocine deben coordinar a trav茅s de sus representantes de H.C. Wainwright.
Lipocine (NASDAQ: LPCN)鞚� 順侅嫚鞝侅澑 瓴疥惮 鞎诫 鞝勲嫭鞐� 欤茧牓頃橂姅 氚旍澊鞓れ牅鞎� 須岇偓搿�, 2025雲� 9鞗� 8鞚紐10鞚检棎 鞐措Μ電� H.C. Wainwright 27th Annual Global Investment Conference鞐� 彀戈皜頃╇媹雼�. 須岇偓 氚滍憸電� 2025雲� 9鞗� 5鞚� 鞓れ爠 7:00 EDT攵�韯� 鞝滉车霅╇媹雼�.
旖橅嵓霟办姢電� 順勳灔 氚� 鞓澕鞚� 順曧儨搿� 歆勴枆霅╇媹雼�. Lipocine 瓴届榿歆勱臣鞚� 鞚茧寑鞚� 氙疙寘鞚� 鞗愴晿鞁滊姅 韴瀽鞛愲姅 H.C. Wainwright 雼措嫻鞛愲ゼ 韱淀暣 鞚检爼 臁办湪鞚� 頃橃嫓旮� 氚旊瀺雼堧嫟.
Lipocine (NASDAQ: LPCN), une soci茅t茅 biopharmaceutique ax茅e sur des solutions orales innovantes, participera 脿 la H.C. Wainwright 27th Annual Global Investment Conference du 8 au 10 septembre 2025. La pr茅sentation de la soci茅t茅 sera disponible 脿 partir du 5 septembre 2025 脿 7h00 EDT.
La conf茅rence se tiendra en pr茅sentiel et en virtuel. Les investisseurs souhaitant des rencontres individuelles avec la direction de Lipocine doivent les organiser via leurs repr茅sentants H.C. Wainwright.
Lipocine (NASDAQ: LPCN), ein Bio颅pharma颅unternehmen, das sich auf innovative orale Wirkstoff颅formulierungen spezialisiert, wird an der H.C. Wainwright 27th Annual Global Investment Conference vom 8. bis 10. September 2025 teilnehmen. Die Pr盲sentation des Unternehmens wird ab dem 5. September 2025 um 7:00 Uhr EDT verf眉gbar sein.
Die Konferenz findet sowohl vor Ort als auch virtuell statt. Investoren, die Einzelgespr盲che mit dem Management von Lipocine w眉nschen, sollten diese 眉ber ihre H.C. Wainwright-Ansprechpartner koordinieren.
- None.
- None.
Presentation Details听
Time:听 听 听 听 听 听 听 听 听 听 听 Available from 7:00 a.m. EDT onwards
Date:听 听 听 听 听 听 听 听 听 听 听 Friday, September 5, 2025
Investors can register for the conference听here. Those interested in arranging a 1x1 meeting with Lipocine should contact their H.C. Wainwright representative.
About Lipocine
Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent听enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs.
Lipocine's clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101 for the potential treatment of epilepsy, LPCN 2203 an oral candidate targeted for the management of essential tremor, LPCN 2401 an oral proprietary anabolic androgen receptor agonist, as an adjunct therapy to incretin mimetics, as an aid for improved body composition in obesity management and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, LPCN 2401 for obesity management, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, our candidate for treatment of metabolic dysfunction-associated steatohepatitis (MASH). TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit听.
听
View original content to download multimedia:
SOURCE Lipocine Inc.
FAQ
When is Lipocine (LPCN) presenting at the H.C. Wainwright Conference 2025?
How can investors attend Lipocine's presentation at the H.C. Wainwright Conference?
How can investors schedule a meeting with Lipocine management at the H.C. Wainwright Conference?
What is the format of the H.C. Wainwright Global Investment Conference 2025?
